Biotech Brass Misled Investors About Cancer Drugs, Suit Says

By Sydney Price · November 13, 2024, 7:17 PM EST

Executives and directors of biotechnology company Agenus Inc. have been hit with a shareholder derivative suit in Massachusetts federal court alleging that the company misled investors about the effectiveness of its...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

IN RE AGENUS INC. STOCKHOLDER DERIVATIVE LITIGATION

Case Number

1:24-cv-12823

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

November 12, 2024